Development of biomarkers in multiple sclerosis

Brain

Volumn 127, Issue 7, 2004, Pages 1463-1478

  Bielekova, Bibiana ^a   Martin, Roland ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Autoimmunity; Immunological biomarkers; Multiple sclerosis; Surrogate markers

Indexed keywords

AUTOANTIBODY; BRAIN DERIVED NEUROTROPHIC FACTOR; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; COMPLEMENT; COMPLEMENT COMPONENT C9; CYTOKINE; CYTOKINE RECEPTOR; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; ISOPROSTANE; NEOPTERIN; NITRIC OXIDE; TAU PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; URIC ACID;

AUTOIMMUNITY; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; DEMYELINATION; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOFLUORESCENCE TEST; LACRIMAL FLUID; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; URINALYSIS;

EID: 3142556134     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh176     Document Type: Review

References (51)

1. Barkhof F, van Walderveen M. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1675-86.
2. Bielekova B, Martin R. Multiple sclerosis: immunotherapy. Curr Treat Options Neurol 1999; 1: 201-20.
3. Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med 2001; 79: 552-65.
4. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-75.
5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
6. Bomprezzi R, Ringner M, Kim S, Bittner ML, Khan J, Chen Y, et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet 2003; 12: 2191-9.
7. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1: 49-67.
8. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers-are we being naive? J Infect Dis 1997; 175: 237-46.
9. Devos D, Forzy G, de Seze J, Caillez S, Louchart P, Gallois P, et al. Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis. J Neurol 2001; 248: 672-5.
10. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60.
11. Food and Drug Administration. Modernization Act of 1997. Title 21 Code of Federal Regulations Part 314 Subpart H Section 314.500, 1997.
12. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2: 566-80.
13. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 170-5.
14. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909-13.
15. Giovannoni G, Thompson EJ. Urinary markers of disease activity in multiple sclerosis. Mult Scler 1998; 4: 247-53.
16. Giovannoni G, Lai M, Thorpe J, Kidd D, Chamoun V, Thompson AJ, et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997; 48: 1557-65.
17. Giovannoni G, Green AJ, Thompson EJ. Are there any body fluid markers of brain atrophy in multiple sclerosis? Mult Scler 1998a; 4: 138-42.
18. Giovannoni G, Kieseier B, Hartung HP. Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998b; 64 Suppl 1: S31-6.
19. Hayward RS, Wilson MC, Tunis SR, Bass EB, Guyatt G. Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The Evidence-Based Medicine Working Group. JAMA 1995; 274: 570-4.
20. Hughes MD. Evaluating surrogate endpoints. Control Clin Trials 2002; 23: 703-7.
21. Hughes MD, De Gruttola V, Welles SL. Evaluating surrogate markers. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 Suppl 2: S1-8.
22. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
23. Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1994a; 271: 389-91.
24. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994b; 271: 703-7.
25. John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, Raine CS, et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 2002; 8: 1115-21.
26. Kraus J, Oschmann P, Engelhardt B, Schiel C, Hornig C, Bauer R, et al. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand 1998; 98: 102-9.
27. Lassmann H. Mechanisms of demyelination and tissue destruction in multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 168-71.
28. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. Remyelination in multiple sclerosis. Mult Scler 1997; 3: 133-6.
29. Lassmann H, Reindl M, Rauschka H, Berger J, Aboul-Enein F, Berger T, et al. A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. Brain 2003; 126: 1347-57.
30. Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41: 347-66.
31. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56: 1505-13.
32. Liedtke W, Weller M, Wietholter H, Dichgans J. Immunological abnormalities in the tears of multiple sclerosis patients. Acta Neurol Scand 1992; 85: 228-30.
33. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500-8.
34. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17.
35. Maas K, Chan S, Parker J, Slater A, Moore J, Olsen N, et al. Cutting edge: molecular portrait of human autoimmune disease. J Immunol 2002; 169: 5-9.
36. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002; 8: 40-50.
37. Molenberghs G, Buyse M, Geys H, Renard D, Burzykowski T, Alonso A. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Control Clin Trials 2002; 23: 607-25.
38. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 2003; 126: 1048-57.
39. NIH-FDA Conference. Biomarkers and surrogate endpoints: advancing clinical research and applications. Abstracts. Dis Markers 1998; 14: 187-334.
40. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000; 54: 1726-33.
41. Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999; 53: 751-7.
42. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6: 67-70.
43. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-40.
44. Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997; 41: 326-33.
45. Rolan P, Atkinson AJ Jr, Lesko LJ. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther 2003; 73: 284-91.
46. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126: 1419-29.
47. Trapp BD, Peterson J, Ransohoff RM, Rudick RM, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. New Engl J Med 1998; 338: 278-85.
48. Wandinger KP, Sturzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001; 50: 349-57.
49. Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003; 361: 2036-43.
50. Whitney LW, Ludwin SK, McFarland HF, Biddison WE. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol 2001; 121: 40-8.
51. Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 2000; 54: 1734-41.